Teva to advance vitiligo antibody TEV-'408 into Phase 2b trials

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/3/2026

1. PANW
2. GTLB
3. DELL
4. MDB
5. HPE
6. GOOGL
7. AVGO
8. SNOW
9. VRTS
10. SPY

Go back to Teva to advance vitiligo antibody TEV-'408 into Phase 2b trials
TEVA PHARMACEUTICAL INDUSTRIES (NYSE: TEVA) Delayed: 37.49 --0 (-0%)
Previous Close $37.49    52 Week High $66.55 
Open $37.49    52 Week Low $37.82 
Day High $37.49    P/E N/A 
Day Low $37.49    EPS $0.00 
Volume 1,646